BR0307871A - Proteìnas contendo domìnio de folistatina - Google Patents

Proteìnas contendo domìnio de folistatina

Info

Publication number
BR0307871A
BR0307871A BR0307871-0A BR0307871A BR0307871A BR 0307871 A BR0307871 A BR 0307871A BR 0307871 A BR0307871 A BR 0307871A BR 0307871 A BR0307871 A BR 0307871A
Authority
BR
Brazil
Prior art keywords
domain
folistatin
proteins
disorders
gdf
Prior art date
Application number
BR0307871-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jennifer J Hill
Neil M Wolfman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0307871A publication Critical patent/BR0307871A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR0307871-0A 2002-02-21 2003-02-21 Proteìnas contendo domìnio de folistatina BR0307871A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35784602P 2002-02-21 2002-02-21
US43464502P 2002-12-20 2002-12-20
PCT/US2003/005150 WO2003072714A2 (en) 2002-02-21 2003-02-21 Follistatin domain containing proteins

Publications (1)

Publication Number Publication Date
BR0307871A true BR0307871A (pt) 2005-04-12

Family

ID=27767537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307871-0A BR0307871A (pt) 2002-02-21 2003-02-21 Proteìnas contendo domìnio de folistatina

Country Status (11)

Country Link
US (3) US7572763B2 (enExample)
EP (1) EP1572934A4 (enExample)
JP (2) JP4429728B2 (enExample)
KR (1) KR20040096592A (enExample)
AU (1) AU2003216345A1 (enExample)
BR (1) BR0307871A (enExample)
CA (1) CA2476654A1 (enExample)
MX (1) MXPA04008149A (enExample)
NO (1) NO20043564L (enExample)
PL (1) PL374966A1 (enExample)
WO (1) WO2003072714A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA04008149A (es) 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
BR0314270A (pt) * 2002-09-16 2005-08-02 Univ Johns Hopkins Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2513251C (en) * 2003-01-14 2013-03-19 Dana-Farber Cancer Institute Cancer therapy sensitizer
US7785587B2 (en) * 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
EP1644406B1 (en) * 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP1729793B1 (en) * 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
WO2005115439A2 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
US9045553B2 (en) 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0609449A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
PT2407486T (pt) 2005-08-19 2018-02-21 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7790161B2 (en) * 2006-03-28 2010-09-07 Wyeth Llc GDF-9/BMP-15 modulators for the treatment of bone disorders
WO2008073351A2 (en) 2006-12-08 2008-06-19 Acceleron Pharma Inc. Uses of cerberus, coco and derivatives thereof
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
KR20170021919A (ko) 2011-10-21 2017-02-28 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
US20180193306A1 (en) 2012-03-23 2018-07-12 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
ES2791778T3 (es) 2012-08-01 2020-11-05 Ikaika Therapeutics Llc Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
JP6475639B2 (ja) 2013-01-25 2019-02-27 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
JP2014151438A (ja) * 2013-02-04 2014-08-25 Koito Mfg Co Ltd レーザー溶着方法
GB201308117D0 (en) * 2013-05-06 2013-06-12 Univ Leuven Kath Inhibitor of calcifying disorders
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2015187977A1 (en) 2014-06-04 2015-12-10 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
WO2018218273A1 (en) * 2017-05-29 2018-12-06 Paranta Biosciences Limited Method of treating hypertension and kidney disease
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
CN111989098A (zh) * 2018-02-20 2020-11-24 埃皮里姆生物股份有限公司 用于治疗肌肉疾病的化合物和组合物
KR20210117271A (ko) 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
MX2019015589A (es) * 2019-12-19 2021-06-21 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular.

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6673534B1 (en) * 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
PT698094E (pt) 1993-05-12 2004-05-31 Inst Genetics Llc Composicoes de bmp-11
DK0716610T3 (da) 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
EP1015468A4 (en) * 1997-08-29 2000-09-06 Human Genome Sciences Inc FOLLISTATINE-3
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US5942420A (en) 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
WO2000011163A1 (en) 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
AU6289999A (en) * 1998-10-15 2000-05-01 Zymogenetics Inc. Follistatin-related protein zfsta2
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
AU6098300A (en) 1999-07-16 2001-02-05 Human Genome Sciences, Inc. Follistatin-3
US7098372B1 (en) * 1999-09-13 2006-08-29 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
CA2389956A1 (en) * 1999-11-03 2001-02-10 Zymogenetics, Inc. Follistatin-related protein zfsta4
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
EP1261712B1 (en) * 2000-03-03 2006-12-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
CA2405550A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA04008150A (es) 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
MXPA04008149A (es) 2002-02-21 2005-06-17 Wyeth Corp Proteinas que contienen dominios de folistatina.
BR0314270A (pt) 2002-09-16 2005-08-02 Univ Johns Hopkins Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
BRPI0609449A2 (pt) * 2005-03-23 2010-04-06 Wyeth Corp detecção de agentes de modulação de gdf-8
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出

Also Published As

Publication number Publication date
US7572763B2 (en) 2009-08-11
WO2003072714A2 (en) 2003-09-04
WO2003072714A3 (en) 2006-12-28
US20110020372A1 (en) 2011-01-27
EP1572934A2 (en) 2005-09-14
US20100047259A1 (en) 2010-02-25
PL374966A1 (en) 2005-11-14
AU2003216345A1 (en) 2003-09-09
CA2476654A1 (en) 2003-09-04
EP1572934A4 (en) 2007-12-19
JP2009286804A (ja) 2009-12-10
US20030180306A1 (en) 2003-09-25
JP2005531505A (ja) 2005-10-20
KR20040096592A (ko) 2004-11-16
NO20043564L (no) 2004-11-03
MXPA04008149A (es) 2005-06-17
JP4429728B2 (ja) 2010-03-10

Similar Documents

Publication Publication Date Title
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
WO2003072715A3 (en) Gasp1: a follistatin domain containing protein
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
BR9814984A (pt) Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio
ECSP055739A (es) Anticuerpos de neutralización contra gdf-8, y sus usos
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
BR0206985A (pt) Anticorpos modificados e métodos de uso
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
BRPI0411020A (pt) perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
BRPI0414049A (pt) compostos e composições como inibidores de proteìna cinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2077 DE 26/10/2010. TEXTO CORRETO: REFERENTE A 7A E 8A ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 PUBLICADO NA RPI 2085 DE 21/12/2009. TEXTO CORRETO: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2077 DE 26/10/2010 E RPI 2085 DE 21/12/2010.